Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > New JUVÉDERM Product

<< Previous

Bullboard Posts

Next >>

Post by Turtle4on May 31, 2023 11:45am

192 Views

Post# 35472630

New JUVÉDERM Product

Interesting study of the new JUVDERM Product Product:

https://news.abbvie.com/news/press-releases/skinvive-by-juvderm-receives-us-fda-approval.htm

TFC-326 should be clearly superior here, and without needles.
Especially the warnings and side effects are interesting.
And they make 1.4 billion a year with JUVDERM

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant